Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have a
narrow therapeutic index and show considerable interindividual variability in their …

In mycophenolate mofetil (MMF)-treated organ transplant recipients, lower mycophenolic
acid (MPA) plasma concentrations have been found in cyclosporine (CsA) compared with …

Mycophenolate mofetil (MMF) is almost completely absorbed from the gut and is rapidly de-
esterified into its active drug, mycophenolic acid (MPA). The main metabolite is …

Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute
rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial …

BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …

Background During pregnancy and nursing, a baby's developing immune system is
intimately exposed to the mother's antigens. To determine whether this exposure is of …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …